Effect of Murivenna Application in Stage 1 Pressure ulcer
Phase 2
- Conditions
- Health Condition 1: L899- Pressure ulcer of unspecified site
- Registration Number
- CTRI/2019/03/018298
- Lead Sponsor
- AMRITA VISHWA VIDYAPEETAM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Volunteers with Stage 1 pressure ulcer.
Exclusion Criteria
Patients having underlying diseases like Diabetes mellitus, malignancy, HIV infection, jaundice and other immuno compromised conditions are excluded.
Persons in the habit of smoking, drug abuse are also excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Murivenna's efficacy in stage 1 pressure ulcer healing?
How does Murivenna compare to standard-of-care treatments for L899 pressure ulcers in clinical outcomes?
Are there specific biomarkers that predict response to Murivenna in early-stage pressure ulcer management?
What adverse events are associated with Murivenna application and how are they managed clinically?
What are the potential combination therapies or competitor drugs for stage 1 pressure ulcer treatment alongside Murivenna?